Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Jun 30, 2021 4:58pm
193 Views
Post# 33474926

RE:RE:While more pleasant than the hammered 44 cent, this recent

RE:RE:While more pleasant than the hammered 44 cent, this recentStocktree and MM are swinging for the fences!!  Getting way up to $0.80 per share by 2040 and end of 2021 respectively.

At the start of 2020 we were at $0.80 per share before Baxter deal, TIGRIS start, multiple FDA approvals for SAMI/DIMI and hiring Dr Kellum.  The share price manipulation dropped us to about half that level.  So if the manipulation stops one would think we'd rise to at least where we were and the achievements should add a sizeable gratuity on top of that.  Absent share price manipulation we should be at least at Paradigm's prognostication of $3.20 to $4.00 per share.

My estimate?  We're $8 to $10 once the tomfoolery and shenanigans stop with promotion of the story to a wider and more Southern audience.  Don't forget that once DIMI approved for home use and PMX approved by FDA we've been successful with all the science.
<< Previous
Bullboard Posts
Next >>